Editorial: Immunotherapy in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).
作者信息
Jamy Omer, Zhou Fuling, Zeidner Joshua
机构信息
Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States.
Department of Hematology, Wuhan University, Wuhan, China.
出版信息
Front Immunol. 2024 Oct 17;15:1501760. doi: 10.3389/fimmu.2024.1501760. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Immunotherapy in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).社论：急性髓系白血病（AML）和急性淋巴细胞白血病（ALL）中的免疫疗法。
Front Immunol. 2024 Oct 17;15:1501760. doi: 10.3389/fimmu.2024.1501760. eCollection 2024.
2
Immunotherapies in acute leukemia.急性白血病的免疫疗法。
Therapie. 2022 Mar-Apr;77(2):241-250. doi: 10.1016/j.therap.2021.12.003. Epub 2021 Dec 6.
3
Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against - mutant acute myeloid leukemia and -rearranged acute lymphoblastic leukemia.FLT3 导向嵌合抗原受体 T 细胞免疫疗法对 - 突变型急性髓系白血病和 - 重排型急性淋巴细胞白血病的强大临床前活性。
Haematologica. 2023 Feb 1;108(2):457-471. doi: 10.3324/haematol.2022.281456.
4
Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia.嵌合抗原受体 T 细胞靶向 NKG2D 配体对急性髓系白血病和 T 细胞急性淋巴细胞白血病显示出强大的疗效。
Front Immunol. 2020 Dec 15;11:580328. doi: 10.3389/fimmu.2020.580328. eCollection 2020.
5
Development of acute lymphoblastic leukemia following treatment for acute myeloid leukemia in children with Down syndrome: A case report and retrospective review of Children's Oncology Group acute myeloid leukemia trials.唐氏综合征患儿急性髓系白血病治疗后继发急性淋巴细胞白血病：病例报告及儿童肿瘤协作组急性髓系白血病临床试验回顾性分析。
Pediatr Blood Cancer. 2019 Aug;66(8):e27700. doi: 10.1002/pbc.27700. Epub 2019 Mar 25.
6
Aberrant expression of ecotropic viral integration site-1 in acute myeloid leukemia and acute lymphoblastic leukemia.嗜异性病毒整合位点-1在急性髓系白血病和急性淋巴细胞白血病中的异常表达。
Leuk Lymphoma. 2015 Feb;56(2):472-9. doi: 10.3109/10428194.2014.924118. Epub 2014 Jun 25.
7
Cytogenetic profile of Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia in Northern Pakistan.巴基斯坦北部急性髓系白血病和急性淋巴细胞白血病的细胞遗传学特征
Pak J Med Sci. 2023 Sep-Oct;39(5):1440-1445. doi: 10.12669/pjms.39.5.6405.
8
Bispecific antibodies in immunotherapy for adult acute leukemia: latest updates from the 65th American Society of Hematology 2023 Annual Meeting.双特异性抗体在成人急性白血病免疫治疗中的应用：第65届美国血液学会2023年年会的最新进展
Expert Opin Biol Ther. 2024 Apr;24(4):221-223. doi: 10.1080/14712598.2024.2333793. Epub 2024 Mar 25.
9
Immunoreactivity of MIC2 (CD99) and terminal deoxynucleotidyl transferase in bone marrow clot and core specimens of acute myeloid leukemias and myelodysplastic syndromes.急性髓系白血病和骨髓增生异常综合征骨髓凝块及核心标本中MIC2（CD99）和末端脱氧核苷酸转移酶的免疫反应性。
Arch Pathol Lab Med. 2006 Feb;130(2):153-7. doi: 10.5858/2006-130-153-IOMCAT.
10
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells.利用基于配体的嵌合抗原受体工程化 T 细胞靶向急性髓细胞白血病中的 FLT3。
J Hematol Oncol. 2018 May 2;11(1):60. doi: 10.1186/s13045-018-0603-7.
本文引用的文献
1
A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges.急性髓系白血病免疫治疗的前景：当前进展与挑战
Front Pharmacol. 2023 Apr 19;14:1151032. doi: 10.3389/fphar.2023.1151032. eCollection 2023.
2
Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia.维奈托克联合化疗用于复发/难治性早期T细胞前体急性淋巴细胞白血病
Leuk Lymphoma. 2021 Sep;62(9):2292-2294. doi: 10.1080/10428194.2021.1897807. Epub 2021 Mar 10.
3
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.阿扎胞苷和维奈托克治疗未经治急性髓系白血病。
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
4
Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy.谈毒素：从考莱毒素到现代癌症免疫疗法。
Toxins (Basel). 2020 Apr 9;12(4):241. doi: 10.3390/toxins12040241.
5
Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer.急性白血病免疫治疗的当前进展：抗体、嵌合抗原受体、免疫检查点及自然杀伤细胞概述
Front Oncol. 2019 Sep 19;9:917. doi: 10.3389/fonc.2019.00917. eCollection 2019.
Zotero 插件